vs
Bowman Consulting Group Ltd.（BWMN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Bowman Consulting Group Ltd.的1.7倍（$219.9M vs $129.0M），Bowman Consulting Group Ltd.净利率更高（1.5% vs -1.0%，领先2.5%），Bowman Consulting Group Ltd.同比增速更快（13.9% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $8.1M），过去两年Bowman Consulting Group Ltd.的营收复合增速更高（16.6% vs 8.0%）
SLR咨询是一家私有的国际可持续发展咨询企业，在欧洲、北美洲、南美洲、大洋洲及非洲均设有办事处。公司以「推动可持续发展落地」为宗旨，凭借遍布全球的专业顾问与技术团队，携手客户共同应对全球最复杂的各类可持续发展挑战。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BWMN vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.7倍
$129.0M
营收增速更快
BWMN
高出11.9%
2.0%
净利率更高
BWMN
高出2.5%
-1.0%
自由现金流更多
OFIX
多$8.7M
$8.1M
两年增速更快
BWMN
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $129.0M | $219.9M |
| 净利润 | $2.0M | $-2.2M |
| 毛利率 | 55.0% | 71.1% |
| 营业利润率 | 3.2% | 0.2% |
| 净利率 | 1.5% | -1.0% |
| 营收同比 | 13.9% | 2.0% |
| 净利润同比 | -66.7% | 92.4% |
| 每股收益（稀释后） | $0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWMNOFIX
| Q4 25 | $129.0M | $219.9M | ||
| Q3 25 | $126.0M | $205.6M | ||
| Q2 25 | $122.1M | $203.1M | ||
| Q1 25 | $112.9M | $193.6M | ||
| Q4 24 | $113.2M | $215.7M | ||
| Q3 24 | $113.9M | $196.6M | ||
| Q2 24 | $104.5M | $198.6M | ||
| Q1 24 | $94.9M | $188.6M |
净利润BWMNOFIX
| Q4 25 | $2.0M | $-2.2M | ||
| Q3 25 | $6.6M | $-22.8M | ||
| Q2 25 | $6.0M | $-14.1M | ||
| Q1 25 | $-1.7M | $-53.1M | ||
| Q4 24 | $5.9M | $-29.1M | ||
| Q3 24 | $771.0K | $-27.4M | ||
| Q2 24 | $-2.1M | $-33.4M | ||
| Q1 24 | $-1.6M | $-36.0M |
毛利率BWMNOFIX
| Q4 25 | 55.0% | 71.1% | ||
| Q3 25 | 53.1% | 72.2% | ||
| Q2 25 | 53.7% | 68.7% | ||
| Q1 25 | 51.4% | 62.8% | ||
| Q4 24 | 53.2% | 69.0% | ||
| Q3 24 | 52.4% | 68.7% | ||
| Q2 24 | 52.5% | 67.8% | ||
| Q1 24 | 50.6% | 67.5% |
营业利润率BWMNOFIX
| Q4 25 | 3.2% | 0.2% | ||
| Q3 25 | 4.2% | -8.3% | ||
| Q2 25 | 7.4% | -7.9% | ||
| Q1 25 | 1.0% | -25.2% | ||
| Q4 24 | 1.2% | -5.3% | ||
| Q3 24 | 0.4% | -9.6% | ||
| Q2 24 | -1.2% | -12.5% | ||
| Q1 24 | -2.8% | -15.6% |
净利率BWMNOFIX
| Q4 25 | 1.5% | -1.0% | ||
| Q3 25 | 5.3% | -11.1% | ||
| Q2 25 | 4.9% | -6.9% | ||
| Q1 25 | -1.5% | -27.4% | ||
| Q4 24 | 5.2% | -13.5% | ||
| Q3 24 | 0.7% | -13.9% | ||
| Q2 24 | -2.0% | -16.8% | ||
| Q1 24 | -1.6% | -19.1% |
每股收益（稀释后）BWMNOFIX
| Q4 25 | $0.13 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.57 | ||
| Q2 25 | $0.34 | $-0.36 | ||
| Q1 25 | $-0.11 | $-1.35 | ||
| Q4 24 | $0.37 | $-0.76 | ||
| Q3 24 | $0.04 | $-0.71 | ||
| Q2 24 | $-0.13 | $-0.88 | ||
| Q1 24 | $-0.11 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.1M | $82.0M |
| 总债务越低越好 | $57.6M | — |
| 股东权益账面价值 | $261.1M | $450.0M |
| 总资产 | $579.7M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资BWMNOFIX
| Q4 25 | $11.1M | $82.0M | ||
| Q3 25 | $16.2M | $62.9M | ||
| Q2 25 | $15.5M | $65.6M | ||
| Q1 25 | $10.7M | $58.0M | ||
| Q4 24 | $6.7M | $83.2M | ||
| Q3 24 | $11.7M | $30.1M | ||
| Q2 24 | $23.1M | $26.4M | ||
| Q1 24 | $11.7M | $27.0M |
总债务BWMNOFIX
| Q4 25 | $57.6M | — | ||
| Q3 25 | $29.8M | $157.2M | ||
| Q2 25 | $32.0M | $157.0M | ||
| Q1 25 | $36.4M | $156.9M | ||
| Q4 24 | $38.1M | $157.0M | ||
| Q3 24 | $36.4M | $118.5M | ||
| Q2 24 | $38.8M | $118.0M | ||
| Q1 24 | $26.8M | $118.2M |
股东权益BWMNOFIX
| Q4 25 | $261.1M | $450.0M | ||
| Q3 25 | $261.8M | $442.5M | ||
| Q2 25 | $249.6M | $458.3M | ||
| Q1 25 | $244.1M | $458.3M | ||
| Q4 24 | $246.1M | $503.1M | ||
| Q3 24 | $243.2M | $525.9M | ||
| Q2 24 | $235.6M | $546.0M | ||
| Q1 24 | $167.3M | $570.3M |
总资产BWMNOFIX
| Q4 25 | $579.7M | $850.6M | ||
| Q3 25 | $510.2M | $832.6M | ||
| Q2 25 | $538.2M | $837.2M | ||
| Q1 25 | $528.7M | $823.1M | ||
| Q4 24 | $505.9M | $893.3M | ||
| Q3 24 | $497.0M | $867.9M | ||
| Q2 24 | $463.4M | $882.0M | ||
| Q1 24 | $420.5M | $906.0M |
负债/权益比BWMNOFIX
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.11× | 0.36× | ||
| Q2 25 | 0.13× | 0.34× | ||
| Q1 25 | 0.15× | 0.34× | ||
| Q4 24 | 0.15× | 0.31× | ||
| Q3 24 | 0.15× | 0.23× | ||
| Q2 24 | 0.16× | 0.22× | ||
| Q1 24 | 0.16× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $8.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 6.3% | 7.6% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.76× | — |
| 过去12个月自由现金流最近4个季度 | $33.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BWMNOFIX
| Q4 25 | $9.4M | $27.7M | ||
| Q3 25 | $10.2M | $12.4M | ||
| Q2 25 | $4.3M | $11.6M | ||
| Q1 25 | $12.0M | $-18.4M | ||
| Q4 24 | $11.9M | $23.7M | ||
| Q3 24 | $6.8M | $11.7M | ||
| Q2 24 | $3.1M | $9.0M | ||
| Q1 24 | $2.5M | $-18.6M |
自由现金流BWMNOFIX
| Q4 25 | $8.1M | $16.8M | ||
| Q3 25 | $10.1M | $2.5M | ||
| Q2 25 | $4.2M | $4.5M | ||
| Q1 25 | $11.0M | $-25.1M | ||
| Q4 24 | $11.7M | $15.2M | ||
| Q3 24 | $6.6M | $6.3M | ||
| Q2 24 | $2.7M | $-360.0K | ||
| Q1 24 | $2.3M | $-29.1M |
自由现金流率BWMNOFIX
| Q4 25 | 6.3% | 7.6% | ||
| Q3 25 | 8.0% | 1.2% | ||
| Q2 25 | 3.4% | 2.2% | ||
| Q1 25 | 9.7% | -13.0% | ||
| Q4 24 | 10.4% | 7.0% | ||
| Q3 24 | 5.8% | 3.2% | ||
| Q2 24 | 2.6% | -0.2% | ||
| Q1 24 | 2.4% | -15.4% |
资本支出强度BWMNOFIX
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.0% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.9% | 3.5% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 0.3% | 5.6% |
现金转化率BWMNOFIX
| Q4 25 | 4.76× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.02× | — | ||
| Q3 24 | 8.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWMN
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
